THE IMPACT OF HLA TYPE I AND ANTI-HLA ANTIBODIES  IN KIDNEY TRANSPLANT PATIENTS

Nguyễn Vân Hương; Nguyễn Duy Thăng; Nguyễn Văn Sơn; Nguyễn Ngọc Hiếu; Vũ Thị Thơm

doi:10.34238/tnu-jst.10886

THE IMPACT OF HLA TYPE I AND ANTI-HLA ANTIBODIES IN KIDNEY TRANSPLANT PATIENTS

About this article

Received: 07/08/24 Revised: 17/11/24 Published: 18/11/24

Authors

1. Nguyen Van Huong , Nguyen Tat Thanh University
2. Nguyen Duy Thang, Hue Central Hospital
3. Nguyen Van Son, Hue Central Hospital
4. Nguyen Ngoc Hieu, University of Medicine and Pharmacy at Ho Chi Minh City
5. Vu Thi Thom, Can Tho Central General Hospital

Abstract

HLA type I plays an important role in the transplantation process - the best treatment method for patients with end-stage renal failure. The purpose of this study was to evaluate the correlation between HLA type I polymorphism and transplant by PCR-SSP test and to determine the impact of anti-HLA antibodies on the rejection process by flow cytometry in kidney transplant patients in the Central and Southern regions of Vietnam. From the study results, it was found that patients indicated for kidney transplantation were mainly concentrated in the age group of 30 - 50, in which the age group of 40 - 50 accounted for the highest rate of 30% (p <0.05). The rate of male patients indicated for transplantation was higher than that of female patients (male: 76%, female: 24%, p <0.05). In the age group (40-50 years), patients with a history of organ resection (gallbladder, colon polyps, spleen, appendix) accounted for 6% (p<0.05), kidney stones (4%, p<0.05), diabetes (2%, p<0.05), hypertension and gout (4%, p<0.05). In particular, patients also carried anti-HLA antibodies with a high PRA % for type I of 58% including Antibodies: A*2, A*24, A*68, A*69, B*45. The alleles HLA-A*23, HLA-A*29, HLA-B*46 and HLA-B*51 appeared in patients indicated for kidney transplantation.

Keywords

Alleles; Organ Transplantation; HLA Type I; PCR-SSP; Transplant rejection

Full Text:

PDF (Tiếng Việt)

References

[1] S. Abramyan et al., Kidney Transplantation, Treasure Island (FL): StatPearls, 2023.

[2] M. M. Ahmed et al., “Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies,” Journal of Immunology Research, vol. 2018, no. 1, pp. 1-18, 2018.

[3] S. C. Palme et al., “Interventions for preventing bone disease in kidney transplant recipients,” Cochrane Database Syst Rev., vol. 2019, no. 10, 2019, doi: 10.1002/14651858.CD005015.pub4.

[4] C.-M. Chen et al., “The Difficulties and Needs of Organ Transplant Recipients during Postoperative Care at Home: A Systematic Review,” Int J Environ Res Public Health, vol. 17, no. 16, 2020, Art. no. 5798.

[5] M. Á. Frutos et al., “Recommendations for living donor kidney transplantation,” Nefrología (English Edition), vol. 42, Supplement 2, pp. 5-132, 2022.

[6] A. Ladányi et al., “HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab,” Pathol Oncol Res., vol. 28, 2022, Art. no. 1610297.

[7] K. Balassa et al., “Haematopoietic stem cell transplants: principles and indications,” British Journal of Hospital Medicine, vol. 80, no. 1, 2018, doi: h10.12968/hmed.2019.80.1.33.

[8] M. M. Althaf et al., “Human leukocyte antigen typing and crossmatch: A comprehensive review,” World J Transplant, vol. 7, no. 6, pp. 339-348, 2017.

[9] V. S. Nguyen, "Research on HLA genotype using PCR - SSP technique and ABO blood group system in kidney transplant patients at Hue Central Hospital," Master's thesis, University of Science - Hue University, 2018.

[10] V. H. Nguyen, N. D. Thang, T. T. H. Phan, V. S. Nguyen, T. M. T. Ngo, K. T. Nguyen, T. N. Y. Nguyen, and N. H. Nguyen, "Human leukocyte antigens class i (hla-i) polymorphism on chronic kidney patients," Vietnam Journal of Biotechnology, vol. 2, pp. 361-366, 2021.

[11] J. R. A. Peña et al., “Anti-HLA antibody testing in hematology patients,” Am J Hematol., vol. 90, no. 4, pp. 361-364, 2016.

[12] F. Ozkul et al., “Effect of age on the outcome of renal transplantation: A single-center experience,” Pak J Med Sci., vol. 32, no. 4, pp. 827-830, 2016.

[13] M. E. Astley et al., “The ERA Registry Annual Report 2020: a summary,” Clinical Kidney Journal, vol. 16, no. 8, pp. 1330-1354, 2023.

[14] A. Jagdale et al., “Chronic Dialysis in Patients with End-Stage Renal Disease: Relevance to Kidney Xenotransplantation,” Xenotransplantation, vol. 26, no. 2, 2019, Art. no. e12471.

[15] X. Zhang et al., “Prevalence and Risk Factors of Gallbladder Stones and Polyps in Liaoning, China,” Front Med (Lausanne), vol. 9, 2022, Art. no. 865458

[16] V. Kosmoliaptsis et al., “Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation,” Clinical Investigation, vol. 86, no. 5, p. 1039, 2014.

[17] M. Kavuzlu et al., “HLA-B*51 Frequency in Transplant Patients and Donors,” Exp Clin Transplant, vol. 22(Suppl 1), pp. 265-269, 2024.

[18] N. V. Le and N. N. Bach, “Characteristics of HLA-Antigens and compatibility in living related-kidnay transplantation at Viet Duc Hospital,” Vietnam Medical Journal, vol. 538, no. 3, pp. 181-185, 2024.

[19] S. Y. Kim et al., “Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients,” BMC Pulm Med., vol. 18, p. 45, 2018.

[20] M. V. de Sousa et al., “Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings,” Ann Transplant, vol. 25, 2020, Art. no. e925488.

DOI: https://doi.org/10.34238/tnu-jst.10886

Refbacks

There are currently no refbacks.



Remember me